Randomized Trial: A Head-to-head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-naïve Patients with Active Psoriatic Arthritis

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial – Annals of Rheumatic Diseases (free)

Commentary: We Have a Winner: Head-to-Head Study Compares Biologics for PsA – MedPage Today (free registration required)